Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy
JF Scarini, L Lavareze, RA de Lima-Souza… - Critical Reviews in …, 2022 - Elsevier
Squamous cell carcinomas (SCC) are the most common malignant tumors that arise in the
head and neck. Despite advances in the management of affected patients, the mortality …
head and neck. Despite advances in the management of affected patients, the mortality …
[HTML][HTML] Glycogen synthase kinase-3β inhibitors as a novel promising target in the treatment of cancer: medicinal chemistry perspective
D Karati, KK Shaoo, KR Mahadik, D Kumr - Results in Chemistry, 2022 - Elsevier
Glycogen synthase kinase-3 beta (GSK-3β) is a desired pharmacological target for cancer
treatment. Despite its role in the development of various cancers, any target directing GSK-3 …
treatment. Despite its role in the development of various cancers, any target directing GSK-3 …
Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator
D Karati, S Mukherjee, S Roy - Medical Oncology, 2024 - Springer
In developing new cancer medications, attention has been focused on novel epigenetic
medicines called histone deacetylase (HDAC) inhibitors. Our understanding of cancer …
medicines called histone deacetylase (HDAC) inhibitors. Our understanding of cancer …
[PDF][PDF] Multi-Fold Computational Analysis to Explore JAK2 and STAT5 Potential Inhibitors for Modulation of Cancer
Background: The Janus kinase 2-Signal Transducer and Activator of the Transcription 5
pathway (JAK2-STAT5 pathway) is a signaling pathway that plays a role in a variety of …
pathway (JAK2-STAT5 pathway) is a signaling pathway that plays a role in a variety of …